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Abstract
Experimental evidence increasingly implicates the b-amyloid peptide in the pathogenesis of Alzheimer’s disease.
b-amyloid filaments dramatically accumulate in the neuritic plaques and vascular deposits as the result of the brain’s
inability to clear these structures. In this paper, we demonstrate that in addition to the intrinsic stability of A b N-42, the
time dependent generation of irreversibly associated A b dimers and tetramers incorporated into A b filaments are
themselves resistant to proteolytic degradation. The presence of post-translational modifications such as isomerization of
aspartyls 1 and 7, cyclization of glutamyl 3 to pyroglutamyl and oxidation of methionyl 35, further contribute to the
insolubility and stability of A b. All these factors promote the accumulation of neurotoxic amyloid in the brains of patients
with Alzheimer’s disease, and should be considered in therapeutic strategies directed towards the dissociation of the brain’s
A b filaments. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
One of the major pathological lesions in the brains
 .of patients with Alzheimer’s disease AD is the
accumulation of 8–10 nm filaments made of the
 .40–42 amino acid long beta-amyloid A b peptide.
These insoluble and undegradable filaments are usu-
ally deposited at the center of the neuritic plaques, in
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the form of cores of amyloid, or in the walls of
cerebral and leptomeningeal vessels. The amyloid
isolated from AD brains after formic acid solubiliza-
tion can be separated by size-exclusion chromatogra-
phy into five components, of these components,
monomeric A b is the only fraction that can be
w xefficiently digested by proteolytic enzymes 1,2 . The
insensitivity of the oligomeric A b components to
proteolysis may also be related to post-translational
modifications. In the AD brain the A b is present as a
heterogeneous mixture of peptides with various N-
w xterminal truncations 1–4 and mostly terminating at
0925-4439r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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w xresidue 40 and 42 1,5 . The longer form is more
abundant in the amyloid of the neuritic plaques while
the shorter peptide predominates in the vascular amy-
w xloid deposits 1,2 . A very insoluble A b peptide,
encompassing residues 17–42, is also found in dif-
w xfuse amyloid deposits 6,7 . The A b peptides present
in the AD brains are also post-translationally modi-
fied to yield substantial quantities of isomerized Asp
at position 1 and 7, hereafter referred as A b 1–42 1,
. w x7 IsoAsp 1,2 , cyclized Glu at position 3 in the form
of pyroglutamyl, henceforth referred as A b 3pE-42
w x8 . In addition, the Met at position 35 is oxidized in
the form of Met sulfone or Met sulfoxide. To compli-
cate the heterogeneity of A b further a variable de-
gree of racemization has taken place at positions: Asp
w x1, Asp 7, Ser 8, and Asp 23 1,9 .
In this paper, we characterize some of the physico-
chemical properties of the various forms of A b
present in the human brain including those post-trans-
lationally modified peptides. We demonstrate that
within the fibrillar amyloid there is a time dependent
irreversible oligomerization of A b into dimers and
tetramers that can no longer be dissociated into
monomers. More importantly, we establish that the
fraction of A b associated into irreversible dimers
and tetramers along with their post-translational mod-
ifications play a crucial role in the stability and
resistance of the amyloid filaments to proteolytic
degradation.
2. Materials and methods
Peptides utilized in this study were: A b 1–28,
A b 17–42, A b 1–40, A b 1–42, A b 3pE-42 and
 .A b 1–42 1,7 IsoAsp . All A b peptides were syn-
 .thesized by California Peptide Research Napa, CA .
Peptides were purified by FPLC on a Superdex 75
 .column Pharmacia and Upjohn, Uppsala, Sweden ,
 . or by reverse phase RP -HPLC C18 column Bio-
.Rad, Richmond, CA and their composition charac-
terized by mass spectrometry, automatic amino acid
analysis and HPLC peptide mapping of tryptic frag-
w xments 1,8 .
The molecular masses of A b 1–40 and A b 1–42
in aqueous buffer were investigated by size exclusion
chromatography on a Synchropak GPC 100 column
equilibrated with 50 mM Tris–HCl, pH 7.4 at a flow
rate of 0.5 mlrmin. Fifty mg of A b 1–40 were
dissolved in 500 ml of 50 mM Tris–HCl, pH 7.4 and
immediately chromatographed. An equal amount of
A b 1–40 was incubated at room temperature for 24 h
in the same buffer and prior to application to the
column centrifuged at 12,000=g for 10 min to
remove aggregated material. Because of its insolubil-
 .ity, A b 1–42 50 mg was either dissolved in 50 ml
of concentrated DMSO or in 50 ml of 80% glass
distilled formic acid, and in both cases rapidly diluted
by the addition of 450 ml of 50 mM Tris–HCl, pH
7.4, and immediately chromatographed as above.
To study the degree of individual dimerization and
tetramerization of the various A b , peptides were
dissolved in the proportion of 1 mgrml of 80%
formic acid and immediately dialyzed Spectrapor 6
.membrane, 1000 Da cutoff against distilledrde-
 .ionized water 4 l for 2 h followed by dialysis
against 100 mM Tris–HCl pH 7.4, 1 mM EDTA until
equilibrium. The specimens were incubated, at 378C
for different periods of time: 12 h and 2, 4, 8 and 12
weeks. At the end of each incubation period, the
volume of each specimen was reduced to 50 ml by
vacuum centrifugation, followed by the addition of
450 ml of 90% formic acid and immediately chro-
matographed on a Superdex 75 column equilibrated
and developed with 80% formic acid at a flow rate of
0.2 mlrmin and monitored at 280 nm.
The proteolytic susceptibility of the various A b
peptides was assessed. One milligram each of the
monomeric A b 1–40, 1–42, 3pE-42 and 17–42 and
1 mg each of the monomeric and dimeric 1–42 1,7
.IsoAsp were dissolved in 1 ml of 80% formic acid
and dialyzed against two changes in distilled water
followed by three changes in 0.1 M ammonium
 . bicarbonate pH 7.8 . Trypsin Worthington Bio-
.chemical, Freehold, NJ hydrolysis was carried out
for 16 h at 378C using an enzyme to substrate ratio of
1:50. The resulting soluble tryptic peptides were sep-
w xarated by C18 RP-HPLC as previously described 1 .
Due to proteolytic resistance and to the hydrophobic
nature of some of the A b peptides, a water insoluble
core precipitated after tryptic digestion. This insolu-
ble core was subsequently dissolved in 80% formic
 .acid and hydrolyzed by cyanogen bromide CNBr .
Cleavage at Met35 splits the hydrophobic C-terminal
domain of A b into more soluble peptides which
were separated by HPLC. The sensitivity to tryptic
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hydrolysis of the newly formed A b 1–42 filaments,
generated after 4 days of incubation in 100 mM
Tris–HCl pH 7.4 at 378C, was compared to an equal
amount of older A b 1–42 preparation, incubated for
46 days under the same conditions. To oxidize the
Met at position 35, 1 mg of A b 1–42 was dissolved
in 1 ml of 80% formic acid followed by the addition
of 20 ml of 30% hydrogen peroxide. The new and
old A b filaments as well as the oxidized peptide
were subsequently submitted to tryptic hydrolysis to
investigate the degree of proteolytic sensitivity fol-
lowing the methods described above. The relative
yields of the enzymatic peptides were measured in
terms of arbitrary absorbance units at 214 nm using
the SpectraSYSTEM Software-PC 1000 Thermo
.Separation Products, Freemont, CA . The number of
peptide bonds in each peptide were considered in the
final calculation. Additionally, the quantities of each
peptide were also calculated in terms of their abun-
dance relative to A b 1–40, the most soluble and
hence the most accessible to hydrolysis of the A b
peptides under investigation.
All A b peptides, as well as their enzymatically
and chemically derived by-products were submitted
to acid hydrolysis. The peptides were hydrolyzed on
a vapor phase system Work Station Waters, Milford,
.MA in 6 M HCl, 1% phenol at 1558C for 90 min.
The amino acid composition of the peptide hydro-
lyzates were automatically determined using the nin-
hydrin reaction Thermo Separation ProductsrPicker-
.ing, Mountain View, CA .
To determine the ability of the different A b
monomers and dimers to promote fibrillogenesis
 .seeding effect , a stock solution of A b 1–40 was
prepared by dissolving 10 mg of this peptide in 1 ml
of 35% acetonitrile and then diluted with buffer 10
.mM Tris–HCl, pH 7.4 to obtain a final concentra-
tion of 1 mgrml of A b. Different ‘seeds’ were
prepared by dissolving each of the following A b
species in 80% formic acid and immediately dialyz-
ing against 10 mM Tris–HCl, pH 7.4: A b 1–40
monomer, A b 1–40 dimer, A b 1–42 monomer,
 .A b 1–42 dimer, A b 1–42 1,7 IsoAsp monomer,
 .A b 1–42 1,7 IsoAsp dimer and A b 3pE-42
monomer. The final concentrations of the seeds were
determined by amino acid analysis. Experimental so-
lutions were made by mixing the seeding peptides
with A b 1–40 stock at a working ratio of 1:10, or
equivalent to 10.9 mM seed: 109 mM A b 1–40 and
incubated at 258C. Aliquots containing 5 mg 10.6
.ml of A b mixture were removed at 0, 24 and 48 h,
diluted into 1 ml of 10 mM thioflavin-T in 50 mM
 .sodium phosphate pH 7.4 and the emission spectra
immediately obtained using a SPF-500C spectro-
 .fluorimeter SLM Instruments, Urbana, IL with exci-
tation and emission wavelengths at 440 and 482 nm,
w xrespectively, as previously described 10 .
3. Results
Size-exclusion chromatography of freshly prepared
 .aqueous solutions of synthetic A b 1–40 100 mgrml
indicated that this peptide readily associates into
dimeric structures without traces of A b polymers. At
the same concentration, about 90% of A b was still
present as a dimeric form after 24 h of incubation
 .Fig. 1 . Freshly made solutions of the more insoluble
A b 1–42, at a concentration of 50 mgrml, also
behaved as dimers but after 24 h of incubation, an
increasing number of polymers were eluted from the
 .chromatographic column Fig. 1 . Thus, at physio-
logical pH and aqueous conditions, A b peptides
readily associate into dimeric structures.
The insolubility of A b in aqueous solutions and
the tendency that these peptides exhibit for associat-
ing into polymeric fibrillar structures is mostly gov-
erned by the overall hydrophobicity. Fig. 2 illustrates
the relative hydrophobicity of the major A b species
found in the AD brain. The shorter A b 1–40 appears
to be the least hydrophobic of the four major species
of A b observed in AD and hence it elutes first in
RP-HPLC. This is followed by those peptides ending
at residue 42, which carry extra two non-polar amino
 .acids Ile–Ala at the C-terminus. They elute as a
 .cluster: A b 1–42 1,7 IsoAsp , A b 1–42 and
A b 3pE-42, between 36.1% and 36.5% of aceto-
 .nitrile Fig. 2 . The most hydrophobic of all the
naturally occurring peptides is the shorter A b 17–42,
 .which eluted at 41.9% acetonitrile Fig. 2 .
Upon incubation in Tris buffer, pH 7.4, a variable
fraction of A b peptides formed formic acid stable
dimericrtetrameric structures within the A b fibrils.
The rate at which these peptides generate oligomers
is dictated by the length and post-translational modi-
fications carried by the different A b peptides. The
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Fig. 1. Size exclusion chromatographic profiles A b 1–40 and
 .  .A b 1–42. The column was calibrated with a insulin MW 5.7
 .  . and b lysozyme MW 14.3 and soybean trypsin inhibitor MW
.  .20.1 ; c shows the trace of A b 1–40 freshly dissolved in 50
 .  .mM Tris–HCl, pH 7.4 100 mgrml ; d represents the profile of
A b 1–40 after 24 h of incubation in Tris buffer. To circumvent
 .the aqueous insolubility of A b 1–42, the peptide 50 mg was
either dissolved in 50 ml of DMSO or in 50 ml of formic acid
and immediately diluted with 450 ml of Tris buffer. The chro-
 .  .matographic profiles of A b 1–42 are shown in e and f ,
respectively. The slope calculated from the polypeptide markers
indicated a major A b fraction at a molecular mass 8.99 kDa
suggesting a dimeric structure. The A b 1–42 also demonstrated
the presence of some aggregates which were eluted between 23
and 27 min.
shorter A b 17–42 showed an initial fast rate of
oligomerization, 7.8% at 12 h, which doubled after
 .12 weeks Fig. 3 . Large differences in the oligomer-
ization of A b 1–40 and A b 1–42 were observed at
both early and late time points. At 12 h the latter
generated 3.3% of associated forms, whereas the
former accounted for only 1.4%. After a 3 month
incubation period a difference in the levels of
oligomers persisted, with A b 1–42 reaching 27%
 .compared to A b 1–40 at only 11% Fig. 3 . Initial
levels of association for both A b 3pE-42 and A b 1–
 .42 1,7 IsoAsp were relatively high at 7.3% and
7.5% at 12 h, respectively. However, at the end of the
3 month period of incubation, the A b 3pE-42 only
matched the A b 1–42 at 27%, whereas the A b 1–42
Fig. 2. Reverse phase HPLC of the major A b peptides present in
the AD brain. The relative hydrophobicity of A b peptides was
investigated using RP-HPLC on a Zorbax 300-SB C3 column
 .250=4.6 mm , using waterr0.05% TFA as solvent A and
acetonitriler0.05% TFA as solvent B. The chromatography was
developed with a linear gradient from 20% to 70% of solvent B
in 60 min at a flow rate of 1 mlrmin, at a constant temperature
of 708C, and monitored at 214 nm.
Fig. 3. Logarithmic regression plot depicting the overall values
obtained for the dimersrtetramers generated by the different A b
peptides at 12 h and 2, 4, 8 and 12 weeks of incubation. Time
projections were obtained by fitting a line to the plotted values.
The A b 1–42 with IsoAsp at positions 1 and 7 showed the fastest
rate of oligomerization, followed by A b 1–42 and A b 3pE-42.
The A b 1–40 and 17–42 exhibit a very slow rate of dimerization
whilst the A b 1–28 peptide is completely incapable of generating
dimers or tetramers.
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 .1,7 IsoAsp generated as much as 37% of oligomeric
forms. Although the shorter A b 1–28 has not been
isolated from the human brain, it has been shown to
w xgenerate filaments in vitro 11,12 . This peptide ap-
parently lacked the ability to make formic acid stable
dimers in either freshly or long standing preparations
 .Fig. 3 . The synthetic A b oligomerization values
were plotted and fitted with logarithmic regression
 .lines Fig. 3 , to probabilistically estimate the times
at which the various synthetic A b peptides reach the
equilibrium ratios 55% monomers and 45%
.dimersrtetramers obtained from the denatured A b
w xfilaments isolated from the AD brain 13 .
As can be appreciated in Fig. 4A, trypsin cleaved
A b at residues 5, 16 and 28 Arg, Lys, Lys, respec-
.tively . Apparently, the presence of residues Ile41
and Ala42 indirectly renders the peptide bond
Lys28–Gly29 less accessible to tryptic hydrolysis.
Due to their relative insolubility, part of the tryptic
peptide residues 29–40 and the total amount of the
peptide residues 29–42 precipitated as an insoluble
core and therefore do not appear in Fig. 4A. These
A b insoluble core were further investigated by solu-
bilization in formic acid and CNBr cleavage. The
yields of the CNBr peptides are shown in Fig. 4B.
Interestingly, the rate of tryptic hydrolysis observed
for A b 3pE-42 was very similar to that seen for
 .A b 1–42, whereas A b 1–42 1,7 IsoAsp monomer
exhibited a reduction in the tryptic hydrolysis at
 .residue Arg5 Fig. 4A . However, the most striking
feature of these data is that the tryptic peptides
 .derived from A b 1–42 1,7 IsoAsp dimer repre-
sented only one quarter of those generated by A b 1–
40 monomer and one half of those produced by
 .A b 1–42 1,7 IsoAsp monomer. We also observed
that oxidation of Met35, to Met sulfone or sulfoxide,
resulted in a decreased proteolytic degradation of
 .A b 1–42 Fig. 4C . Following 46 days of incubation,
A b 1–42 filaments were about 3.5 times less suscep-
tible to hydrolysis relative to values obtained for
 .4-day old filaments Fig. 4D . Furthermore, large
quantities of undigested A b6–35 were recovered
after CNBr cleavage of the insoluble tryptic core.
Lastly, tryptic hydrolysis of A b 17–42 was very
poor, amounting to only a small fraction of that
 .observed for A b 1–40 Fig. 4A .
We investigated the intrinsic ability of the irre-
versible dimers extracted from A b filaments on
 .Fig. 4. Proteolytic sensitivity of A b monomers and dimers. A
The relative amounts of tryptic peptides resulting from the diges-
tion of 1 mgrml of monomeric A b 1–40, A b 1–42, A b 3pE-42,
 . A b 1–42 1,7 IsoAsp and A b 17–42 as well as A b 1–42 1,7
.IsoAsp dimer. The insoluble cores left after tryptic digestion
were treated with CNBr. The resulting CNBr peptides are shown
 .in B . Small amounts of the tryptic peptide residues 17–28 were
 .also recovered in the insoluble core. C A comparison of the
susceptibility to tryptic hydrolysis between the non-oxidized
 .A b 1–42 Non PAOX , and A b 1–42 which was submitted to
 .performic acid oxidation PAOX to convert Met to Met sulfox-
 .ide. D The relative amounts of tryptic and CNBr peptides
derived from the digestion of A b 1–42 after 4 days and 46 days
of incubation.
A b 1–40 fibrillogenesis. Examination of the cross
b-pleated structure contained in solutions of A b 1–40
by thioflavin-T fluorimetry reveals that A b 1–40
alone exhibits marked increases in b-sheet content
after 24 and 48 h incubations relative to the initial
 .state p-0.001; Fig. 5 . The inclusion of A b 1–42
 .and A b 1–42 1,7 IsoAsp formic acid stable dimers
as seed molecules at a molar ratio of 1:10;
.seed:A b 1–40 had no significant effects on the fluo-
rescent emissions of A b 1–40. In contrast to this
behavior, monomers of A b 1–42, A b 1–42 1,7
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Fig. 5. Thioflavin-T fluorimetric analysis of A b fibril formation.
Freshly prepared solutions of A b 1–40 were seeded with
 .monomers or dimers of A b 1–42, A b 1–42 1,7 IsoAsp and
A b 3pE-42. Polymerization of A b 1–40 was largely enhanced by
all three A b N-42 monomeric species. Dimers did not promote
cross b-pleated sheet formation, since their polymerization kinet-
ics remain at the basal level exhibited by A b 1–40 alone.
.IsoAsp and A b 3pE-42 at the same 1:10 seed:A b 1–
40 ratio significantly catalyzed the aggregation pro-
cess, as evidenced by significant increases in emis-
 .sions at 24 h Fig. 5 .
4. Discussion
The association of A b into dimeric structures in
aqueous buffers is not totally unexpected. Molecular
modeling of A b 1–42 suggest that in order to shield
the thermodynamically unfavorable hydrophobic do-
mains from the environment, the A b monomer needs
to interact with another A b molecule to generate a
w xmore stable dimer 14 . This prediction has been
substantiated by our experiments demonstrating that
in freshly prepared solutions both A b 1–40 and
A b 1–42 at mM levels behave as dimeric structures.
Using size exclusion chromatography, Hilbich et al.
w x15 showed that A b prepared in aqueous solution
contains dimers which were in the b-conformation
according to circular dichroism spectroscopy. Gel
filtration analysis of A b in 100 mM TrisrHCl, pH
w x7.4 16,17 or in 10 mM phosphate buffer, pH 7.2
containing up to 40% acetonitrile, dimeric forms of
A b were, again, eluted without traces of monomeric
w xforms 18 . The presence of A b dimers in aqueous
buffers at physiological pH was also recently con-
firmed by fluorescence Resonance Energy Transfer
w x19 .
Destructive A b filaments increasingly accumulate
during the evolution of AD as the result of the brain’s
inability to enzymatically degrade these structures.
Isolated neuritic plaque cores from the AD brain are
totally resistant to the action of proteolytic enzymes
w x20 . To break the chemical bondage of the AD
amyloid filaments, it is necessary to dissolve the
w xamyloid cores in powerful denaturing agents 1 .
Chemical analysis of the resulting fractions has re-
vealed a complex mixture of proteins, glycoproteins,
lipids and carbohydrates from which A b peptide
appears to be the major component, amounting to
approximately 70–80% of the total amyloid mass
w x1,21 . Although the in situ amyloid resistance to
degradation can in part be due to the lipid and
saccharide moieties, the A b isolated from AD brain
and its synthetic equivalents have demonstrated in-
trinsic properties which render these peptides resis-
tant to proteolytic attack. Among these are the time
dependent accumulation of post-translational modifi-
cations and the generation of formic acid stable dimers
and tetramers which are either irreversibly denatured
or covalently cross-linked.
Our observations suggest that the hydrophobic C-
termini of the amyloid peptide is involved in the
initial generation of formic acid stable dimeric and
tetrameric structures. The ability to form oligomers,
after 3 months of incubation, was extraordinarily
enhanced by the presence of two extra amino acids
 .Ile41–Ala42 over the shorter A b N-40 peptide
which irreversibly aggregated at a significantly slower
 .rate 11% vs. 27% after 3 months of incubation. A b
peptides lacking the C-terminal domain such as
A b 1–28 do not dimerize, whereas the initial rate of
dimerization is enhanced in the A b 17–42 peptide.
Interestingly, the latter peptide is mainly present,
( )Y.-M. Kuo et al.rBiochimica et Biophysica Acta 1406 1998 291–298 297
although not exclusively, in the diffuse deposits which
are not associated with apparent neuronal pathology
w x6,7 .
The N-terminal region of those A b peptides ter-
minating in residue 42 also plays an important role in
the long term dimerization and tetramerization. Al-
though, there appears to be little difference in hy-
 .drophobicity among A b 1–42 1,7 IsoAsp , A b 1–42
and A b 3pE-42, the highest rate of oligomerization
after 3 months of incubation was scored by the
 .A b 1–42 1,7 IsoAsp at 37%, which is about 10%
higher than those values achieved by A b 1–42 and
A b 3pE-42. When the dimerizationrtetramerization
rates of A b were calculated, a time projection of
about 22 weeks was obtained for the A b 1–42 1,7
.IsoAsp to reach the 45% value of dimericrtetra-
meric forms observed in the filament from AD brain
w x13 , which was considerably faster than for A b 1–42
and A b 3pE-42 which required 60 weeks. According
to these projections, the A b 1–40 and A b 17–42 will
never reach the 45% value during the normal life
expectancy of a human being.
Other structural factors are responsible for the A b
resistance to proteolytic degradation. The two non-
polar residues at the C-terminus greatly increase the
overall hydrophobicity of the oligomeric A b N-42.
The A b peptides, A b 1–42 and A b 3pE-42 are more
insoluble in aqueous solvents and less susceptible to
proteolytic attack than the shorter A b 1–40, which in
w xits fibrillar form also resists proteolytic attack 22 .
Removal of the A b N-terminal region by putative
aminopeptidases permits the cyclization of residue
Glu3 into pyroglutamyl, blocking further degradation
of A b. We have recently demonstrated that this
post-translational modification is present in more than
50% of the total A b in the amyloid of the neuritic
w xplaques 8 . The monomeric and dimeric forms of
 .A b 1–42 1,7 IsoAsp are even less prone to tryptic
hydrolysis than A b 1–42 probably because of the
conformational changes induced by the a- to b-
carbon shift in the progression of the peptide bonds
w x23 . Finally, the most hydrophobic of the peptides
A b 17–42, which rapidly aggregates in aqueous solu-
tions, appears to be almost inaccessible to the action
of trypsin.
Regarding the oxidation of Met35, this change
significantly decreased the sensitivity of A b 1–42 to
proteolysis. This was an unexpected finding since the
introduction of one or two oxygens in the middle of
the non-polar C-terminal sequence residues 29–
.40r42 of A b , would theoretically increase the hy-
dration of this domain, making it more accessible. As
it happens, oxidation of Met35 may enhance the
hydrogen bonding between the antiparallel b-sheets
of A b.
Atomic force microscopy of the brain’s purified
dimeric A b demonstrated globular structures, 3.4 nm
diameter, which at higher concentrations did not
polymerize into fibrillar structures but formed ran-
w xdom aggregates 13 . In contrast to the dimers, the
monomeric A b derived from the human brain rapidly
w xpolymerized into filamentous structures 13 . Follow-
ing these observations we tested the capacity of
monomeric and dimeric forms of synthetic A b to
serve as seeds for the polymerization of A b 1–40. It
appears that formic acid stable dimeric A b 1–42 and
 .A b 1–42 1,7 IsoAsp derived from amyloid fibrils
are unable to catalyze the polymerization of A b 1–40,
whereas their monomeric counterparts, including
A b 3pE-42, promoted fibrillogenesis. The inability of
dimers to polymerize A b 1–40 indicates conforma-
tional changes that fail to support fibrillogenesis.
Thus, formic acid stable dimers found in vivo and in
vitro may represent a terminal stage of A b confor-
mation.
5. Conclusion
We previously described a pool of water soluble
w xoligomeric A b in AD brain 24 in addition to formic
acid stable dimersrtetramers isolated from amyloid
w xfibrils 13 . The latter species of A b were also
present upon extraction from AD brains with guani-
dine thiocyanate at neutral pH, indicating that these
dimersrtetramers of A b are not an artifact of the
formic acid treatment. Rather, these stable dimersrte-
tramers appeared to be terminally denatured. Herein,
we show that formic acid stable A b dimersrtetra-
mers are also generated within fibrils made of syn-
thetic peptides. The proportions of these formic acid
stable and undegradable A b dimersrtetramers in-
crease with time under physiological conditions. Our
data suggest that A b oligomerization helps explain
the reduced clearance of this peptide from brain, due
to its increased resistance to proteolytic degradation.
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The degree of protease resistance reflects the ability
of the different A b peptides to irreversibly aggregate
into stable dimers and tetramers, a process enhanced
by the presence of Ile41 and Ala42, N-terminal post-
translational modifications and oxidized Met. The
proclivity of these different peptides for oligomeriza-
tion also parallels those species of A b that accumu-
late most in AD brains in the form of amyloid
plaques. Based on these results, it may be speculated
that A b exist in two different forms. Those molecules
that contribute to the formation of insoluble fibrils as
w xrecently suggested by Walsh et al. 17 and those
molecules which represent a pool of soluble A b. In
the AD brain, both insoluble and soluble species of
w xA b appear to have inherent toxicities 25,26 .
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